North America Rare Neurological Disease Treatment Market

Historic Data: 2017-2018   |   Base Year: 2019   |   Forecast Period: 2020-2027

Analysis Indication (Narcolepsy, Amyotrophic Lateral Sclerosis, Alzheimer’s Disease, Multiple Sclerosis, Spinal Muscular Atrophy (SMA), Duchenne Muscular Dystrophy, Other Indication); Drug Type (Organic Compounds, Biologics); Distribution Channel (Online Pharmacies, Hospital Pharmacies, Retail Pharmacies); Mode of Administration (Oral, Injectables) and Country


No. of Pages: 139    |    Report Code: TIPRE00010245    |    Category: Life Sciences

North America Rare Neurological Disease Treatment Market
Buy Now

The North America rare neurological disease treatment market is expected to reach US$ 6,113.29 Mn in 2027 from US$ 3,184.10 Mn in 2019. The market is estimated to grow with a CAGR of 8.7% from 2019-2027.

 

The growth of the market is driven by factors such as the rising prevalence of rare neurological diseases, increasing awareness about rare diseases, and robust pipeline drugs in the North America region. However, higher cost of rare neurological disease treatments is likely to restrain the market growth to a certain extent.

 

A large group of rare diseases that have inefficient diagnoses and treatments are the neurological disease. These diseases target the nervous system, which include the brain, spinal cord, and all the nerves that run throughout the human body. There is no surety regarding the onset of the diseases; some can strike during childhood, whereas others can affect even highly aged people.

 

In the world of medicine, rare neurological diseases represent significant burden on health systems in terms of disease diagnosis, treatment, and management. Some of the majorly observed rare neurological diseases comprises narcolepsy, amyotrophic lateral sclerosis, Alzheimer’s disease, multiple sclerosis, spinal muscular atrophy (SMA), Duchenne muscular dystrophy, and others. According to a data published by National Institutes of Neurological Disorders and Stroke in 2019, 7,000 rare neurological diseases have been registered in the US. Additionally, according to the same study, these conditions are responsible for significant number of morbidity and mortality. Additionally, increasing prevalence of rare neurological diseases is expected to drive the growth of the rare neurological disease treatment market during the forecast period.

 

Rapid developments in healthcare and drug discovery are leading to the introduction of new therapeutic solutions for the treatment of rare neurological diseases. Authorities such as World Health Organization, National Institute of Neurological Disorders and Stroke, and National Institutes of Health are taking constructive steps to encourage the research activities to find a remedy for rare neurological disease treatment. For instance, Neurological disorders, which include more than 1,000 conditions that disrupt the brain and nervous system, affect an estimated 100 million Americans, nearly one third of the US population. With the annual cost of neurological disorders already approaching $800 billion, new treatments that both modify and prevent neurological disease are more critical than ever. Such increasing awareness and developments for rare neurological diseases are likely to boost the growth of the rare neurological disease treatment market in North America during the forecast period.

 

The increasing use of rare neurological disease treatment in medical treatment cases in North America is expected to drive rare neurological disease treatment market the growing pharmaceuticals industry in the country create a lucrative opportunity and the presence of an established market for rare neurological disease treatment.

 

Mexico Rare neurological disease treatment Market Revenue and Forecasts to 2027 (US$ Bn)

 

Mexico Rare neurological disease treatment Market Revenue and Forecasts to 2027 (US$ Bn)
Get more information on this report

North America Rare Neurological Disease Treatment Strategic Insights

Strategic insights for the North America Rare Neurological Disease Treatment provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

strategic-framework/north-america-rare-neurological-disease-treatment-market-strategic-framework.webp
Get more information on this report

North America Rare Neurological Disease Treatment Report Scope

Report Attribute Details
Market size in 2019 US$ 3,184.10 Million
Market Size by 2027 US$ 6,113.29 Million
Global CAGR (2019 - 2027) 8.7%
Historical Data 2017-2018
Forecast period 2020-2027
Segments Covered By Indication
  • Narcolepsy
  • Amyotrophic Lateral Sclerosis
  • Alzheimer's Disease
  • Multiple Sclerosis
  • Spinal Muscular Atrophy
  • Duchenne Muscular Dystrophy
  • Other Indication
By Drug Type
  • Organic Compounds
  • Biologics
By Distribution Channel
  • Online Pharmacies
  • Hospital Pharmacies
  • Retail Pharmacies
By Mode of Administration
  • Oral
  • Injectables
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Market leaders and key company profiles
  • Allergan plc.
  • Bayer AG
  • GlaxoSmithKline plc.
  • Johnson & Johnson Services Inc.
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd
  • Takeda Pharmaceutical Company Limited
  • Get more information on this report

    North America Rare Neurological Disease Treatment Regional Insights

    The geographic scope of the North America Rare Neurological Disease Treatment refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

    geography/north-america-rare-neurological-disease-treatment-market-geography.webp
    Get more information on this report

     

    NORTH AMERICA RARE NEUROLOGICAL DISEASE TREATMENT – MARKET SEGMENTATION

    North America Rare Neurological Disease Treatment Market - By Indication

    • Narcolepsy
    • Amyotrophic Lateral Sclerosis
    • Alzheimer’s Disease
    • Multiple Sclerosis
    • Spinal Muscular Atrophy (SMA)
    • Duchenne Muscular Dystrophy
    • Other Indications

    North America Rare Neurological Disease Treatment Market - By Drug Type

    • Organic Compounds
    • Biologics

    North America Rare Neurological Disease Treatment Market - By Distribution Channel

    • Online Pharmacies
    • Hospital Pharmacies
    • Retail Pharmacies

    North America Rare Neurological Disease Treatment Market - By Mode of Administration

    • Oral
    • Injectable

    North America Rare Neurological Disease Treatment Market - By Country

    • US
    • Canada
    • Mexico

    North America Rare Neurological Disease Treatment Market - Companies Mentioned

    • Allergan plc.
    • Bayer AG
    • GlaxoSmithKline plc.
    • Johnson & Johnson Services Inc.
    • Merck & Co. Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi
    • Teva Pharmaceutical Industries Ltd
    • Takeda Pharmaceutical Company Limited

    The List of Companies - North America Rare Neurological Disease Treatment Market

    The List of Companies - North America Rare Neurological Disease Treatment Market

    1. Allergan plc.
    2. Bayer AG
    3. GlaxoSmithKline plc.
    4. Johnson & Johnson Services Inc.
    5. Merck & Co. Inc.
    6. Novartis AG
    7. Pfizer Inc.
    8. Sanofi
    9. Teva Pharmaceutical Industries Ltd
    10. Takeda Pharmaceutical Company Limited

     

    Frequently Asked Questions
    How big is the North America Rare Neurological Disease Treatment Market?

    The North America Rare Neurological Disease Treatment Market is valued at US$ 3,184.10 Million in 2019, it is projected to reach US$ 6,113.29 Million by 2027.

    What is the CAGR for North America Rare Neurological Disease Treatment Market by (2019 - 2027)?

    As per our report North America Rare Neurological Disease Treatment Market, the market size is valued at US$ 3,184.10 Million in 2019, projecting it to reach US$ 6,113.29 Million by 2027. This translates to a CAGR of approximately 8.7% during the forecast period.

    What segments are covered in this report?

    The North America Rare Neurological Disease Treatment Market report typically cover these key segments-

    • Indication (Narcolepsy, Amyotrophic Lateral Sclerosis, Alzheimer's Disease, Multiple Sclerosis, Spinal Muscular Atrophy, Duchenne Muscular Dystrophy, Other Indication)
    • Drug Type (Organic Compounds, Biologics)
    • Distribution Channel (Online Pharmacies, Hospital Pharmacies, Retail Pharmacies)
    • Mode of Administration (Oral, Injectables)

    What is the historic period, base year, and forecast period taken for North America Rare Neurological Disease Treatment Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the North America Rare Neurological Disease Treatment Market report:

  • Historic Period : 2017-2018
  • Base Year : 2019
  • Forecast Period : 2020-2027
  • Who are the major players in North America Rare Neurological Disease Treatment Market?

    The North America Rare Neurological Disease Treatment Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • Allergan plc.
  • Bayer AG
  • GlaxoSmithKline plc.
  • Johnson & Johnson Services Inc.
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd
  • Takeda Pharmaceutical Company Limited
  • Who should buy this report?

    The North America Rare Neurological Disease Treatment Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the North America Rare Neurological Disease Treatment Market value chain can benefit from the information contained in a comprehensive market report.

    Available Report Formats

    pdf-format excel-format pptx-format
    Buy Now